July 26, 2022 02:40 PM EDT
FDA+
Manufacturing

St. Louis-based API man­u­fac­tur­er slammed with FDA warn­ing let­ter over 'per­va­sive mold,' qual­i­ty is­sues

Zachary Brennan

Senior Editor

The growth of API man­u­fac­tur­ing in In­dia and Chi­na has led to nu­mer­ous warn­ing let­ters and lots of ques­tion marks around qual­i­ty con­trol and da­ta …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times